0B68 Den, Robert B. - Thomas Jefferson University - Thomas Jefferson University

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis
  2. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy
  3. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer
  4. Uncertainties encountered in implementation of adaptive planning with in vivo dosimeters
  5. Is robotic arm stereotactic body radiation therapy 'virtual high-dose rate brachytherapy' effective for prostate cancer? An analysis of comparative effectiveness using published data
  6. Adjuvant versus salvage radiation therapy for prostate cancer patients with adverse pathologic features: Comparative analysis of long-term outcomes
  7. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes
  8. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer
  9. The retinoblastoma tumor suppressor modulates DNA repair and radioresponsiveness
  10. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy
  11. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation
  12. Practical guide to the use of radium 223 dichloride
  13. High dose rate brachytherapy boost for prostate cancer: A systematic review
  14. A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer
  15. Introduction
  16. The lag time in initiating clinical testing of new drugs in combination with radiation therapy, a significant barrier to progress?
  17. Effect of docetaxel on safety and efficacy of radium-223
  18. RNA biomarkers associated with metastatic progression in prostate cancer: A multi-institutional high-throughput analysis of SChLAP1
  19. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma
  20. Adjuvant vaginal cuff brachytherapy for high-risk, early stage endometrial cancer